Republished with permission of Amy Tenderich of DiabetesMine.com
For at least three consecutive years now at the annual ADA Conference, we keep hearing about a rumored switchover from the A1c as the gold standard average glucose measurement. Instead, we'll get something new and supposedly easier to understand: a new measure that more closely reflects the mg/dL (and international mmol/l) numbers we all get on our home glucose meters. This new test is now dubbed the eAG (estimated average glucose).
One of the big news announcements Scientific Sessions this week was the results of a large international study that supposedly underscores the accuracy of the eAG. In this 10-center study, 507 volunteers with diabetes had their A1c translated into eAG readings and compared with their running daily BG results, if I understood the press materials correctly. "Study investigators found a simple linear relationship," the ADA press release states.
Also stated: "Patients find it difficult ...
Reprinted with permission of Amy Tenderich of diabetesmine.com . Remember that little discussion about abandoning the established A1c for a new Average Glucose (AG) measurement? Well, guess what? This is pretty much the "dumbest idea ever floated" in diabetes, according to my favorite irreverent industry expert, David Kliff of Diabetic Investor . Indeed, the ADA and a number of other powerful health organizations -- the International Federation of Clinical Chemistry (IFCC), European Association for the Study of Diabetes (EASD), and International Diabetes Federation (IDF) -- now have an agreement in place to evaluate the accuracy of the A1c and potentially switch to the new AG units, contingent on results of an international study currently underway. The new standard apparently won't change the chemistry of the test itself, but only the "reference method," i.e. how the machines that conduct the tests are calibrated, and how the results ar...
The Food and Drug Administration surprised almost everyone on March 24 by approving the DexCom STS Continuous Glucose Monitoring System . Even DexCom’s President and CEO Andrew Rasdal seems to have been surprised.
He told analysts in a conference call on March 27 that he had expected an “approvable letter” requesting more information. I was surprised as anyone, even though a few months ago I bought stock in the company.
Even more surprising is that Rasdal says that they will start selling the STS system immediately and anywhere in the country. This is in marked contrast to the Medtronic Diabetes marketing strategy for the other continuous sensor, the Guardian RT. While it works out the reimbursement issue, Medtronic is limiting sales to just seven large cites .
Getting health insurance coverage is the big challenge for all continuous sensors simply because they are so expensive. Rasdal told analysts that those of us who can afford the out-of-pocket costs will be the company’s first ...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.